Conventional tumor markers such as carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are widely used but limited by low sensitivity and specificity, particularly in early-stage disease (5). This evidence concerns the gene CEACAM5 and neoplasm.